SCHEMBL5406020

SCHEMBL5406020

COc1ccc(CS[C@@H]2C[C@@H](CCC(=O)N(C)OC)N(S(=O)(=O)c3ccc4ccccc4c3)C2)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.44
LMNA P02545 1/20 0.44
GAA P10253 1/20 0.44
PKM P14618 1/20 0.44
HTT P42858 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
MME P08473 2/20 0.37
ACE P12821 2/20 0.37
ECE1 P42892 2/20 0.37
POLB P06746 1/20 0.36
PPARG P37231 1/20 0.36
NCOA2 Q15596 1/20 0.36
NCOA1 Q15788 1/20 0.36
CTDSP1 Q9GZU7 1/20 0.36
NCOA3 Q9Y6Q9 1/20 0.36
MMP1 P03956 10/20 0.36
MMP13 P45452 10/20 0.36
MMP9 P14780 8/20 0.36
MMP3 P08254 6/20 0.36
MMP2 P08253 4/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5406027 1.00 ALDH1A1 (0.44) ALDH1A1LMNAGAAPKMHTT
SCHEMBL7135066 0.90 MMP1 (0.44) ALDH1A1LMNAGAAPKMHTT
SCHEMBL7140975 0.90 MMP1 (0.44) ALDH1A1LMNAGAAPKMHTT
SCHEMBL7144857 0.89 LMNA (0.47) ALDH1A1LMNAGAAPKMHTT
SCHEMBL7134640 0.89 LMNA (0.47) ALDH1A1LMNAGAAPKMHTT
SCHEMBL7135171 0.89 ALDH1A1 (0.47) ALDH1A1LMNAGAAPKMHTT
SCHEMBL7151570 0.89 ALDH1A1 (0.47) ALDH1A1LMNAGAAPKMHTT
SCHEMBL7150109 0.85 MME (0.45) ALDH1A1LMNAGAAPKMHTT
SCHEMBL5410375 0.85 HTRA1 (0.34) ALDH1A1HTTSMN1; SMN2MMP1MMP13
SCHEMBL5410379 0.85 HTRA1 (0.34) ALDH1A1HTTSMN1; SMN2MMP1MMP13

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7189756-B2 Pyrrolidine derivatives HOFFMAN-LA ROCHE INC. (US) 2007-03-13 US disclosed
US-20040242672-A1 Useful as inhibitors of metalloproteases, e.g. zinc proteases; effective in treating disease states associated with vasoconstriction such as high blood pressure, coronary disorders, cardiac insufficiency, renal and myocardial ischaemia, renal insufficiency, dialysis, cerebral ischaemia AEBI JOHANNES (CH) 2004-12-02 US disclosed
US-6790860-B2 USEFUL AS INHIBITORS OF METALLOPROTEASES, E.G. ZINC PROTEASES; EFFECTIVE IN TREATING DISEASE STATES ASSOCIATED WITH VASOCONSTRICTION HOFFMANN-LA ROCHE INC. 2004-09-14 US disclosed
US-20030199569-A1 Pyrrolidine derivatives AEBI JOHANNES (CH) 2003-10-23 US disclosed
EP-1303486-A1 PYRROLIDINE DERIVATIVES AS METALLOPROTEASE INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2003-04-23 EP disclosed
US-20020040146-A1 Pyrrolidine derivatives F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) 2002-04-04 US disclosed
WO-2002008185-A1 PYRROLIDINE DERIVATIVES AS METALLOPROTEASE INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2002-01-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030199569-A1 Pyrrolidine derivatives PREP, PEPD, MMP3 ALDH1A1 1186/4885LMNA 4696/4885GAA 413/4885
US-20020040146-A1 Pyrrolidine derivatives PREP, PEPD, MMP3 ALDH1A1 1186/4885LMNA 4696/4885GAA 413/4885
US-20040242672-A1 Useful as inhibitors of metalloproteases, e.g. zinc proteases; effective in treating disease states associated with vasoconstriction such as high blood pressure, coronary disorders, cardiac insufficiency, renal and myocardial ischaemia, renal insufficiency, dialysis, cerebral ischaemia MMP1, PEPD, MMP25 ALDH1A1 2463/4885LMNA 4507/4885GAA 256/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.